Effectiveness of Treating NELL1-Positive Idiopathic Membranous Nephropathy on Clinical Outcomes, Serum Cytokine Levels (IL-6, IL-10, IL-2, IL-17), Nutritional Status, and Immune Responses

Clinical Outcomes, Serum Cytokine Levels (IL-6, IL-10, IL-2, IL-17) in Idiopathic Membranous Nephropathy

  • Kang Li Department of Nephrology, Cangzhou Central Hospital, Cangzhou, Hebei, 061000, China.
  • Yanqiu Yu Department of Nephrology,Cangzhou Central Hospital
  • Xiaojing Liu Department of Nephrology,Cangzhou Central Hospital
DOI: https://doi.org/10.5937/jomb0-56892
Keywords: Glucocorticoids, Tacrolimus, NELL, Idiopathic Membranous Nephropathy, Nutritional Status, Inflammatory response

Abstract


Objective: This study aimed to evaluate the therapeutic effects of glucocorticoids (GCs) combined with tacrolimus (TAC) in the treatment of Neural Epidermal Growth Factor-Like 1 (NELL1)-positive idiopathic membranous nephropathy (IMN), with a focus on clinical outcomes, nutritional status, and inflammatory response.

Methods: A total of 84 NELL1-positive IMN patients from Cangzhou Central Hospital (January 2020 – February 2024) were randomly assigned to a research group (GCs + TAC) and a control group (GCs alone). The research group received methylprednisolone (0.5g), prednisone (0.5 mg/kg), and tacrolimus (0.05 mg/kg/day), while the control group was treated with methylprednisolone and prednisone alone. Clinical parameters, including renal function, blood glucose, lipids, nutritional proteins, and cytokine levels (IL-6, IL-10, IL-2, IL-17), were measured at baseline and after six months of treatment. Nutritional status was assessed using the Nutritional Risk Screening 2002 (NRS 2002).

Results: There were no significant differences in clinical efficacy or adverse reactions between the two groups. However, the research group exhibited significant improvements in renal function, glycemic control, lipid profile, and nutritional status (P < 0.05). Furthermore, the research group showed a more favorable cytokine profile, with greater reductions in pro-inflammatory cytokines (IL-6, IL-17) and increases in anti-inflammatory cytokines (IL-10, IL-2) compared to the control group (P < 0.05). Both groups had comparable safety profiles, with no significant increase in adverse events.

Conclusion: The combination of GCs and TAC is an effective and safe therapeutic option for NELL1-positive IMN, improving clinical outcomes, maintaining nutritional stability, and modulating immune responses without increasing adverse reactions.

References

1. Ronco P, Beck L, Debiec H, Fervenza FC, Hou FF, Jha V, et al. Membranous nephropathy. Nat Rev Dis Primers. 2021;7(1):69.
2. Dantas M, Silva LBB, Pontes BTM, Dos Reis MA, de Lima PSN, Moyses Neto M. Membranous nephropathy. J Bras Nefrol. 2023;45(2):229-43.
3. Gu Y, Xu H, Tang D. Mechanisms of Primary Membranous Nephropathy. Biomolecules. 2021;11(4).
4. Li Z, Le W, Zhang H, Chen D, Chen W, Zhu S, et al. Clinical features of anemia in membranous nephropathy patients: a Chinese cohort study. Ren Fail. 2023;45(1):2152692.
5. Ardalan M, Ahmadian E, Hosseiniyan Khatibi SM, Rahbar Saadat Y, Bastami M, Bagheri Y, et al. Microbiota and glomerulonephritis: An immunological point of view. Am J Med Sci. 2022;364(6):695-705.
6. Srivastava SP, Zhou H, Setia O, Liu B, Kanasaki K, Koya D, et al. Loss of endothelial glucocorticoid receptor accelerates diabetic nephropathy. Nat Commun. 2021;12(1):2368.
7. Zhang Y, Hu YT, Lv JC, Zhang H. Corticosteroids in the treatment of IgA nephropathy: lessons from the TESTING trial. Pediatr Nephrol. 2023;38(10):3211-20.
8. Lv J, Wong MG, Hladunewich MA, Jha V, Hooi LS, Monaghan H, et al. Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial. JAMA. 2022;327(19):1888-98.
9. El Karoui K, Fervenza FC, De Vriese AS. Treatment of IgA Nephropathy: A Rapidly Evolving Field. J Am Soc Nephrol. 2024;35(1):103-16.
10. Campbell KN. Oral Glucocorticoids for IgA Nephropathy. JAMA. 2022;327(19):1872-4.
11. Sethi S, Debiec H, Madden B, Charlesworth MC, Morelle J, Gross L, et al. Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy. Kidney Int. 2020;97(1):163-74.
12. Aliyu M, Zohora FT, Anka AU, Ali K, Maleknia S, Saffarioun M, et al. Interleukin-6 cytokine: An overview of the immune regulation, immune dysregulation, and therapeutic approach. Int Immunopharmacol. 2022;111:109130.
13. Saraiva M, Vieira P, O'Garra A. Biology and therapeutic potential of interleukin-10. J Exp Med. 2020;217(1).
14. Spolski R, Li P, Leonard WJ. Biology and regulation of IL-2: from molecular mechanisms to human therapy. Nat Rev Immunol. 2018;18(10):648-59.
15. McGeachy MJ, Cua DJ, Gaffen SL. The IL-17 Family of Cytokines in Health and Disease. Immunity. 2019;50(4):892-906.
16. Bao N, Gu M, Yu X, Wang J, Gao L, Miao Z, et al. Immunosuppressive treatment for idiopathic membranous nephropathy: An updated network meta-analysis. Open Life Sci. 2023;18(1):20220527.
17. Kondrup J, Allison SP, Elia M, Vellas B, Plauth M, Educational, et al. ESPEN guidelines for nutrition screening 2002. Clin Nutr. 2003;22(4):415-21.
18. Wu L, Lai J, Ling Y, Weng Y, Zhou S, Wu S, et al. A Review of the Current Practice of Diagnosis and Treatment of Idiopathic Membranous Nephropathy in China. Med Sci Monit. 2021;27:e930097.
19. Zhao Q, Dai H, Liu X, Jiang H, Liu W, Feng Z, et al. Helper T Cells in Idiopathic Membranous Nephropathy. Front Immunol. 2021;12:665629.
20. Schutte-Nutgen K, Tholking G, Suwelack B, Reuter S. Tacrolimus - Pharmacokinetic Considerations for Clinicians. Curr Drug Metab. 2018;19(4):342-50.
21. Caifeng S, Jingsheng Z, Yi L, Xueshi H, Zhanyou W, Haiou P, et al. Effect of treatment with Fufang Huangqi decoction on dose reductions and discontinuation of pyridostigmine bromide tablets, prednisone, and tacrolimus in patients with type I or II myasthenia gravis. J Tradit Chin Med. 2022;42(5):810-7.
22. Fang Y, Luo Y, Lou J, Chen J. Atypical late-onset severe gastritis in immune dysregulation, polyendocrinopathy, enteropathy, and X-linked (IPEX) syndrome: 2 case reports. Medicine (Baltimore). 2021;100(3):e24318.
23. Mieli-Vergani G, Vergani D, Czaja AJ, Manns MP, Krawitt EL, Vierling JM, et al. Autoimmune hepatitis. Nat Rev Dis Primers. 2018;4:18017.
24. Esteves GP, Mazzolani BC, Smaira FI, Mendes ES, de Oliveira GG, Roschel H, et al. Nutritional recommendations for patients undergoing prolonged glucocorticoid therapy. Rheumatol Adv Pract. 2022;6(2):rkac029.
25. Gawrieh S, Dasarathy S, Tu W, Kamath PS, Chalasani NP, McClain CJ, et al. Randomized trial of anakinra plus zinc vs. prednisone for severe alcohol-associated hepatitis. J Hepatol. 2024;80(5):684-93.
26. Mazzucconi MG, Rodeghiero F, Avvisati G, De Stefano V, Gugliotta L, Ruggeri M, et al. Prednisone vs high-dose dexamethasone in newly diagnosed adult primary immune thrombocytopenia: a randomized trial. Blood Adv. 2024;8(6):1529-40.
27. Chen HX, Cheng Q, Li F, He QN, Cao Y, Yi ZW, et al. Efficacy and safety of tacrolimus and low-dose prednisone in Chinese children with steroid-resistant nephrotic syndrome. World J Pediatr. 2020;16(2):159-67.
28. Hirano T. IL-6 in inflammation, autoimmunity and cancer. Int Immunol. 2021;33(3):127-48.
29. Kuwabara T, Ishikawa F, Kondo M, Kakiuchi T. The Role of IL-17 and Related Cytokines in Inflammatory Autoimmune Diseases. Mediators Inflamm. 2017;2017:3908061.
30. Ip WKE, Hoshi N, Shouval DS, Snapper S, Medzhitov R. Anti-inflammatory effect of IL-10 mediated by metabolic reprogramming of macrophages. Science. 2017;356(6337):513-9.
31. Teisseyre M, Cremoni M, Boyer-Suavet S, Ruetsch C, Graca D, Esnault VLM, et al. Advances in the Management of Primary Membranous Nephropathy and Rituximab-Refractory Membranous Nephropathy. Front Immunol. 2022;13:859419.
Published
2025/04/11
Issue
Vol. 44 No. 6 (2025): Journal of Medical Biochemistry
Section
Original paper

Copyright (c) 2025 Kang Li

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.

Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.